Telix Pharma Ltd (TLX)
Hi Market Matters Team Can I please have your current view on Telix. Currently trading around $10.40. Morgan Stanley have a price target $24.60. Would you be buying? regards Deb
The Latest Q&A
Answer
Hi Debbie,
Valuing stocks like TLX is extremely difficult, we thought their result last month was good and at the time said we were cautiously bullish ~$10 covered Here.
Despite a tough 2025 marked by regulatory setbacks, pricing pressure in PSMA imaging and delays to TLX591 data, we believe the company is positioned for a turnaround in 2026. Growth should continue in the PSMA PET imaging business, helped by Gozellix’s favourable reimbursement, longer shelf life and easier scheduling, which could expand use across hospitals and academic centres. We also expect new safety data for TLX591 in early 2026, while upcoming regulatory resubmissions for Pixclara and Zircaix could remove key uncertainties and improve investor sentiment.
- With revenue growth looking strong we think this is the time to consider TLX and can see a test of at least $15 in 2026, but caution it’s likely to be a choppy journey.
